Successful Pregnancy and Delivery After Frozen-thawed Embryo Transfer Following the Third Discontinuation of Tyrosine Kinase Inhibitor in a Woman with Chronic Myeloid Leukemia

Kosuke Takayama; Shin Fujisawa; Takayuki Sakuma; Kodai Hasegawa; Kengo Katsuki; Masahiro Akimoto; Ayako Matsumura; Yuki Nakajima; Takuya Miyazaki; Mariko Murase; Hideaki Nakajima

doi:10.2169/internalmedicine.3322-23

Kosuke Takayama, Shin Fujisawa, Takayuki Sakuma, Kodai Hasegawa, Kengo Katsuki, Masahiro Akimoto, Ayako Matsumura, Yuki Nakajima, Takuya Miyazaki, Mariko Murase, Hideaki Nakajima

Author information

Kosuke Takayama
Department of Hematology, Yokohama City University Medical Center, Japan
Shin Fujisawa
Department of Hematology, Yokohama City University Medical Center, Japan
Takayuki Sakuma
Department of Hematology, Yokohama City University Medical Center, Japan
Kodai Hasegawa
Department of Hematology, Yokohama City University Medical Center, Japan
Kengo Katsuki
Department of Hematology, Yokohama City University Medical Center, Japan
Masahiro Akimoto
Department of Hematology, Yokohama City University Medical Center, Japan
Ayako Matsumura
Department of Hematology, Yokohama City University Medical Center, Japan
Yuki Nakajima
Department of Hematology, Yokohama City University Medical Center, Japan
Takuya Miyazaki
Department of Hematology, Yokohama City University Medical Center, Japan
Mariko Murase
Reproductive Medicine Center, Yokohama City University Medical Center, Japan
Hideaki Nakajima
Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Japan

Keywords: pregnancy, chronic myeloid leukemia, tyrosine kinase inhibitor, assisted reproductive technology

JOURNAL OPEN ACCESS Advance online publication

Article ID: 3322-23

DOI https://doi.org/10.2169/internalmedicine.3322-23

Details

Abstract

Assisted reproductive technology is a viable option for pregnant women with chronic myeloid leukemia. We herein report the case of a patient who underwent successful fertility treatment with frozen embryo preservation at 36 years of age, followed by embryo transfer at 39 years of age, thus resulting in pregnancy and delivery after a third discontinuation of tyrosine kinase inhibitors (TKI). Despite the difficulty of long-term TKI withdrawal, the patient's strong desire for a baby led to a successful pregnancy and delivery with no apparent deformities or abnormalities. Thus, our case highlights the importance of collaboration between reproductive medicine physicians and hematologists.

Corresponding author

Register with J-STAGE for free!